CoreFirst Bank & Trust Makes New Investment in Pfizer Inc. (NYSE:PFE)

CoreFirst Bank & Trust purchased a new stake in Pfizer Inc. (NYSE:PFE) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 8,534 shares of the biopharmaceutical company’s stock, valued at approximately $226,000.

A number of other institutional investors also recently modified their holdings of PFE. Retirement Wealth Solutions LLC bought a new position in Pfizer in the fourth quarter valued at about $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer during the 4th quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer during the 4th quarter valued at approximately $28,000. Noble Wealth Management PBC acquired a new position in Pfizer during the 4th quarter worth approximately $31,000. Finally, Curio Wealth LLC bought a new position in Pfizer in the 4th quarter valued at approximately $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE opened at $26.13 on Tuesday. The firm has a fifty day simple moving average of $26.15 and a 200 day simple moving average of $27.02. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a market capitalization of $148.21 billion, a PE ratio of 18.53, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the prior year, the business earned $0.10 EPS. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of several research analyst reports. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Bank of America reissued a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Citigroup lowered their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Finally, UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.